Patrys Limited (AU:PAB) has released an update.
Patrys Limited has announced promising preclinical results for its deoxymabs PAT-DX1 and PAT-DX3 in treating ANCA vasculitis, a serious autoimmune disease affecting small blood vessels. These studies have shown that the deoxymabs can reduce inflammation and kidney damage without suppressing the immune system, potentially offering a new therapeutic option with fewer side effects than current treatments. The findings were presented at a major international vasculitis workshop, highlighting the potential of Patrys’ antibody platform for vasculitis and other autoimmune diseases.
For further insights into AU:PAB stock, check out TipRanks’ Stock Analysis page.
